You are here

  • Home
  • Archive
  • Volume 10, Issue 12
  • Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

 

Online download statistics by month:

Online download statistics by month: December 2022 to September 2025

AbstractFullPdf
Dec 202210701083281
Jan 202310891096417
Feb 2023524530172
Mar 2023409409119
Apr 202332832884
May 2023357358123
Jun 2023341343126
Jul 202332232389
Aug 2023331331100
Sep 202327227295
Oct 2023244250122
Nov 2023372376118
Dec 2023311313109
Jan 2024164166114
Feb 202419619696
Mar 2024257258150
Apr 2024221221147
May 2024290293115
Jun 2024220222110
Jul 202421221280
Aug 2024136135124
Sep 202410010193
Oct 2024172172102
Nov 202420220395
Dec 2024211216113
Jan 2025166166120
Feb 2025200200100
Mar 2025166166105
Apr 2025199203112
May 2025164165109
Jun 2025909060
Jul 2025110
Sep 2025110
Total933893993900